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a b s t r a c t
Background: Inﬂuenza virus (IFV) isolates obtained from mammalian cell cultures are valuable reagents
used for vaccine production, antigenic characterization, laboratory assays, and epidemiological and evo-
lutionary studies. Complete genomic comparison of IFV isolates with their original clinical specimens
provides insight into cell culture-driven genomic changes whichmay sequentially alter the virus pheno-
type.
Objectives: The genome of the viral isolates and of the viruses in the clinical specimens was examined
by deep sequencing in order to determine nucleotide heterogeneity (measured number of variances or
numbers of mixed bases) as a marker for IFV population diversity.
Study design: Clinical respiratory specimenswere collected between July andOctober 2012 and identiﬁed
by RT-PCR as positive for inﬂuenza A H3N2 or H1N1, or inﬂuenza B. The viruses in the clinical specimens
were ampliﬁed usingmammalian cell culture. Next generation sequencing (NGS)was used to investigate
genomic differences between IFV isolates and their corresponding clinical specimens.
Results: There was less nucleotide heterogeneity in 5 of 6 viral isolates compared to the corresponding
clinical specimens, especially for inﬂuenza B. A phylogenetic analysis of the hemagglutinin (HA) gene
consensus sequences obtained from deep and Sanger sequencing showed that the viral isolates and their
corresponding clinical specimens contained the same IFV strains with less than 5% pair-wise genetic
distance.
Conclusion: The IFV sequence data analysis detected a substantial decrease in nucleotide heterogeneity
from clinical specimens to viral cultures in 5 out of 6 investigated cases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Inﬂuenza viruses (IFVs),members of the orthomyxoviridae fam-
ily, circulate worldwide and are a major global health threat.
Continuouslyevolving IFVsaccumulate changes in theviral genome
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resulting in subpopulation diversity and emergence of new strains.
This leads to annual epidemics and occasional pandemics. Host
immunity, zoonotic vectors and other environmental and eco-
logical factors can drive viral genetic variations and antigenic
modiﬁcation [1]. Genetic variation can be the result of point
mutations leading to antigenic drift, gene reassortment leading to
genetic shift, defective-interfering particles, and RNA recombina-
tion altering the IFV genome [2].
Currently, IFV isolates obtained from mammalian cell cultures
aremainly utilized for genetic and antigenic characterization using
sequencing and hemagglutination inhibition (HI) assays [3,4]. This
information is crucial for monitoring the circulating strains in
endemic regions and to assess the evolution of viruses and emer-
genceofnovel virulenceanddrug resistance traits. This information
is also used to determine the composition of seasonal inﬂuenza
vaccines. Because inﬂuenza vaccine production relies on viral
http://dx.doi.org/10.1016/j.jcv.2015.04.010
1386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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ampliﬁcation in fertilized chicken eggs or mammalian cell culture
[5–9], it is critical to accurately measure the viral subpopulations
in cell culture isolates and to understand how they differ from the
original primary clinical specimens.
Several studies have documented how IFV isolates differ from
the viruses found in clinical specimens [1,10,11]. Azzi et al. found
that inﬂuenza H1N1 is antigenically different after cell culturing
[10]. Zhirnov et al., speciﬁcally investigated thematrix (M), hemag-
glutinin (HA), neuromidase (NA) andnon-structural (NS) genes and
detected several alterations in the sequences of human/canine cell
culture isolates compared to the original clinical specimens [1].
Roedig et al., reported changes in the glycosylation patterns after
cultivation using Sanger sequencing [11]. However, a comparison
of the complete genome sequences of inﬂuenza subpopulations
between clinical respiratory specimens and viral isolates has not
yet been reported. Deep sequencing has been shown to have the
capacity to provide high quality and large volumes of genomic
sequences. It has been shown to detect low frequency muta-
tions and the presence of quasispecies [12]. Examination of the
full-length genome of inﬂuenza virus A (13.6 kb) and B (14.6 kb),
including all 8 genomic segments: RNA polymerase PB1 gene
(2341nt); RNA polymerase PB2 gene (2300nt), RNA polymerase
PA gene (2233 nt), Hemmaglutinin HA gene (1765 nt), matrix M
gene (1027 nt), nonstructural NS protein coding gene including
nuclear export protein NEP gene (890nt), nucleoprotein NP gene
(1565nt) and neuraminidase NA gene (1413nt) with additional NB
protein (210-249) are essential for understanding the evolution of
inﬂuenza B under cultivation.
2. Objectives
In this study, we utilized deep sequencing to compare
nucleotide heterogeneity at genomic positions between inﬂuenza
viral isolates and their original primary clinical specimens.
Nucleotide heterogeneity and pair wise genetic distanceswere uti-
lized to monitor the changes in viral genetic variability detected in
samples. Measuring the genomic differences caused by the ampli-
ﬁcation of IFVs in mammalian cell cultures provides important
information relevant for vaccine manufacturers and scientists in
general.
3. Study design
3.1. Clinical data and demographics information of clinical
samples
Nasopharyngeal swabs were collected in Universal Transport
Media-UTM (UTM) (Copan Diagnostics Inc., Corona, USA) from
6 patients with acute inﬂuenza-like-illness (ILI) enrolled during
surveillance studies from July to October 2012. One clinical spec-
imen was collected in Nepal and the other ﬁve in Thailand. All 6
subjects (VIROAF 1–6) were found positive for inﬂuenza by Quick-
Vue (Quidel, Inc., SanDiego,USA) andequal volumesofRNA fromall
sampleswere later conﬁrmedby inﬂuenza rRT-PCRandHI (27). The
studies were approved by the Institutional Review Boards (IRBs)
of Pramongkutlao (PMK) Hospital in Bangkok Thailand, the Nepal
Health Research Council in Kathmandu, Nepal, and theWalter Reed
Army Institute of Research (WRAIR) as appropriate. For each clini-
cal specimen, IFVwas ampliﬁed inMadinDarby canine as described
previously and conﬁrmed by inﬂuenza HI [14].
3.2. Sample preparation from viral isolates and corresponding
clinical specimens for deep sequencing reactions
Sample preparation and nucleotide quantitation procedures for
Illumina MiSeq Platform followed a previously described method
[13], with the exception of an additional centrifugation step at
6200× g for 10min at 4 ◦C and DNaseI (PreAnalytiX, QIAGEN,
Franklin Lakes, USA) treatment at 37 ◦C for 15min for the clinical
specimens. For the control experiments testing the effects of the
concentrations on nucleotide heterogeneity, 10−1 to 10−4 dilutions
of the original viral isolates were used for the sample preparation.
An internal control, 1% PhiX was utilized for the efﬁciency of DNA
incorporation and error rate during DNA sequencing on cartridges
of 2×150 and 2×250 according to the manufacturer’s protocol
(Illumina, Hayward, USA).
3.3. Sequence data analysis
Eighty-ﬁve percent to 90% of sequence reads analyzed by the
Sequencing Analysis Viewer (SAV) (Illumina, Hayward, USA) had a
quality control (QC) of base-calling score of ≥Q30. The ≥Q30 score
indicates 99.9% accuracy of base calling at a particular sequence
position. The identiﬁcation of viruses was conducted by 2 proce-
dures: de novo assembly by Trinity [15] and “resequencing” or
read-mapping alignment of the obtained sequence reads to ref-
erence sequences using MiSeq Reporter program (MSR), which
used Burrows–Wheeler Aligner (BWA) for sequence read align-
ment [16,17]. Contigs, consensus sequences obtained from de
novo assembly, were identiﬁed as a particular organism based on
the top hits with high identity from “blastn” against GENBANK
database entitled nt20130708 [18]. GENBANK accession numbers
for VIROAF 1-6 are KJ577146-KJ577193 as previously described in
[13] for viral isolates and KJ848671-KJ848715 for clinical speci-
mens, respectively. The SRA submission number is SRP056409. The
identiﬁcation of each sample was used to compare with the results
from the alignment with MSR.
The details of data analysis by MSR with the default set-
tings were described in Rutvisuttinunt et al., 2013 (22): GATK
program was used for variance calling [19,20] and BWA for
alignment. Brieﬂy, references used in alignment analysis from
GenBank of IFVs include A/Brisbane/11/ 2010 (H3N2) (CY121792-
CY121799), A/California/07/ 2009 (H1N1), (KC781781-KC781788),
and B/Wisconsin/01/2010 (CY115183-CY115190). For phyloge-
netic tree analysis of HA gene, we used the following IFV references
for inﬂuenza A: H3N2
A/Victoria/361/2011 vaccine 2012-2014 (KC306165),
A/Perth/16/2009 vaccine 2009-2011 (GQ293081), A/Thailand/CU-
B590/2009 (GQ902818), H1N1 A/California/07/2009 vaccine
2009-2014(GQ906804), A/Thailand/CU-H88/2009 (HM446345).
For inﬂuenza B we used the inﬂuenza B Yamagata lineage:
B/Massachusetts/02/2012 vaccine 2013-2014 (KC892118) and
B/Brisbane/60/2008 vaccine 2013-2014 (CY115151).
Bam ﬁles and VCF ﬁles by MSR provided measurements of
nucleotide heterogeneity. Nucleotide heterogeneity wasmeasured
by the genetic variances (as manifested by numbers of sequence
sites contain variances or mixed bases) at single genomic positions
from deep sequence reads. The default setting for calling the vari-
ances was 100. The Bam and VCF ﬁles were further analyzed for
quality and variances by Integrative Genomics Viewer (IGV) [21].
Further analysis of the variances’ derived synonymous and non-
synonymous mutations in sequence reads found above limit of
detection (LOD, sequence reads with depth of coverage equal to
10) required IGV [21], MySQL (http://dev.mysql.com), SNPer [22]
and visualization. Statistical analysis of the data comparisons was
conductedwith R Statistical Analysis Environment (version 2.15.3).
The correlation test used was ‘Pearson Correlation’ tool from the
website http://www.vassarstats.net/rdiff.html
3.4. Sample preparation for Sanger sequencing and
pyrosequencing reaction
A subset of samples was sequenced by Sanger sequenc-












Number of all variances (nucleotide heterogeneity)a observed in the primary specimens and viral isolates.
Total numbers of variancesa detected in 8 inﬂuenza gene fragments
(further mutation characterization (N &S) was conducted for samples
with DOC>10)
No Names Types DOCb Variances (1) PB2 (2) PB1 (3) PA (4) HA (5) NP (6) NA or NBNA (7) M (8) NEP
1 A/Thailand/VIROAF1/2012 (H3N2) Clinical 329.6 6 1S 2S 1N 0 1N 0 0 1N
Isolate 930.7 5 1S 1N/1S 0 0 1S 1N 0 0
2 A/Thailand/VIROAF2/2012 (H3N2) Clinical 3.8c 10 0 1 2 0 1 5 0 1
Isolate 830.7 4 0 1S 0 2N/1S 0 0 0 0
3 B/Thailand/VIROAF3/2012 Clinical 17.5 140 19S 1N/7S 3N/32S 8S 4N/27S 7N/3S 5N/11S 6N/7S
Isolate 2513.2 0 0 0 0 0 0 0 0 0
4 B/Thailand/VIROAF4/2012 Clinical 3.1c 71 3 1 21 8 13 19 1 5
Isolate 2884.9 2 0 0 1N 0 0 0 0 1N
5 A/Nepal/VIROAF5/2012 (pdmH1/N1) Clinical 4.7c 50 6 5 4 14 9 0 7 5
Isolate 1268.4 2 0 1S 0 1N 0 0 0 0
6 A/Thailand/VIROAF6/2012 (H3N2) Clinical 1.1c 2 0 0 1 0 1 0 0 0
Isolate 1701.1 4 0 1S 0 1N 0 1N/1S 0 0
a The number of variances: number of all mixed bases present at the certain genetic position in the sequence reads regardless of the depth of coverage. The variant ﬁlter quality cutoff was set for 100 as default.
b Coverage: median depth of coverage of the sequence reads in the complete genome.
c indicates low coverage (depth<10) below the cutoff (DOC=10), insufﬁcient for further characterization. N and S abbreviated from synonymous (silent) and nonsynonymous mutations, respectively. The values of DOC are in
inverse correlation (r2 =−0.762.) with Ct values from real-time RT-PCR from both clinical specimens and viral isolates. The Ct values are listed as follows: (i) VIROAF1: 15.18 and 13.8, (ii) VIROAF2: 24.39 and 14.07, (iii) VIROAF3:












Nonsynonymous mutations, drug resistance SNPs and speciﬁc antigenic sites in the variances.
Variances Speciﬁc drug resistance sites Speciﬁc antigenic sites
No Names Types Coverage Tot Synonymous Nonsynonymous FluA H3N2a FluA H1Nb Flu Bc A,B, C, D & E Nonsynonymous mutations
1 A/Thailand/VIROAF1/2012 Clinical 329.6 6 3/6 3/6 – N/A N/A – R26K (NP), M1(NEP), F480L(PA)
Isolates 930.7 5 3/5 2/5 Yese N/A N/A – D151Ne(NA), I517V (PB1)
2 A/Thailand/VIROAF2/2012 Clinical 3.8e 11 – – – – – – –
Isolates 830.7 5 3/5 2/5 – N/A N/A – N232K (HA), N241K (HA)
3 B/Thailand/VIROAF3/2012 Clinical 17.5 140 114/140 26/140 N/A N/A – – 26 Nonsynonymous Mutationsd
Isolates 2513.2 0 – – – – – – –
4 B/Thailand/VIROAF4/2012 Clinical 3.1e 68 – – – – – – –
Isolates 2884.9 2 0/2 2/2 N/A N/A – – X727Y (PA),
M1T (NEP)
5 A/Nepal/VIROAF5/2012 Clinical 4.7e 51 – – – – – – –
Isolates 1268.4 2 1/2 1/2 N/A – N/A – R526G
6 A/Thailand/VIROAF6/2012 Clinical 1.1e 2 – – – – – – –
Isolates 1701.1 4 2/4 2/4 N/A N/A – – N241D (HA),
V241L (NA)
a Drug resistance for Oseltamivir in Inﬂuenza A H3N2 (Laplate et al. [37]): S31N (M2), E119, D151, R292, N294 (NA).
b Drug resistance for Oseltamivir in inﬂuenza A H1N1 (Deyde et al. [38]): S31N (M2), H274Y(NA).
c Drug resistance for Oseltamivir in inﬂuenza B: E117, R150, D197, I221, S249, H273, R374, G407 (NA).
d 26 Mutations found in VIROAF3 clinical specimen: (1) NBNA: C123R, P262Q, G356D, D371G, *375Q, V385I, T456I; (2) NP: S23P, T29A, V233I, I534V, (3) NEP: D120N, G284S, I300T, V301I, S305G, G305D; (4) M: L271P, Q297R,
V308I, F313S, L315P (5) PB1: T457A (6) PA: D234N, M294R, A670V.
e Indicates low coverage of the sequence depth (<10) or below the cutoff (DOC=10); the synonymous and nonsynonymous mutations were not further examined as indicated by dash line.
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Fig. 1. Maximum likelihood phylogenetic tree of HA gene utilizing GTR+G+ I model. HA gene sequences of VIROAF1-6 from either clinical specimen (CS) or viral isolates
(VI) were obtained by Sanger sequencing (S) or MiSeq (M) and analyzed against vaccine reference strains (*) and current circulating inﬂuenza viruses in Thailand. Accession
numbers and inﬂuenza types are indicated in the diagram. Brackets designate types and subtypes of inﬂuenza on the right side of the tree. Bootstrap of at least equal or
greater than 70 is demonstrated next to the node of the tree.
position 41 of specimen ID VIROAF2, 5mL of extracted RNA
was reverse transcribed by SuperScriptTM III High Fidelity
Enzyme Mix (One-step RT-PCR System with Platinum® Taq
High Fidelity, Invitrogen, USA) with the HA42-F14-biotinylated
primer (5′-TTGCTTTGAGCTACATTCTAT GTC-3′), HA42-R78
primer 5′-CGTGCTGTTGTCATTTCCA-3′ and HA42-R59-seq primer
5′—GGAAGTTTTTGAGCGAA-3′. Amplicon bands were identiﬁed by
gel electrophoresis prior to pyrosequencing reaction (PyroMarkTM
Gold Reagents, QIAGEN, Hilden, Germany). Pyrosequencing data
was analyzed by PyroMarkTM Q96 ID Equipment and Software
(PyroMark Q96 2.5.7, QIAGEN, Hilden, Germany).
4. Results
4.1. clinical data and inﬂuenza virus subtype characterization
Clinical specimens were collected from six patients (3–29yrs)
initially enrolled in an inﬂuenza-like-illness (ILI) surveillance study
in 2012. Only one participant received seasonal inﬂuenza vaccine
on 29 September 2011 and none had received antiviral treatments.
Clinical specimens and their correspondingviral isolates yielded
identical IFV types/subtypes as determined by rRT-PCR and HI.
The sensitivity of molecular and serology assays are able to detect
the strains of the viruses. The quantify of virus was increase after
culturing as observed by higher numbers of nucleic acid quantity
and lower RT-PCR threshold cycle (Ct) values (Table 1). Further-
more, the sequence read depths ormedian depth of coverage (DOC)
obtained from all viral isolates were at least 50–2000 folds higher
than the read depths obtained from their corresponding clinical
specimens, which corresponded to the quantity of viral genetic
materials by sequence reads alignment.
4.2. Viruses genomic classiﬁcation
Identical genomic consensus sequences of all twelve samples (6
isolates and6clinical specimensofVIROAF1-6)wereobtained from
alignment method and de novo assembly method. The maximum
likelihood tree (Fig. 1) showed thatbothclinical specimensandviral
isolates of VIROAF1, VIROAF2 and VIROAF6 fell in the inﬂuenza A
H3N2 reference group. The VIROAF3 and VIROAF4 were grouped
with the inﬂuenza B references whereas the VIROAF5 fell in the
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Fig. 2. The composition of mixed bases (cytosine (C) and thymine (T)) at position 41 (DOC=394) leads to synonymous mutation in HA gene VIROAF2 viral isolate. The base
composition was assessed by: (A) Sanger sequencing (* indicate the mixed peaks suggesting the presence of a mixture of C and T); (B) deep sequencing by MiSeq and; (C)
pyrosequencing.
inﬂuenza AH1N1 references. In addition, the pair-wise genetic dis-
tance was calculated to be less than 5% for all six pairs of viral
isolates and clinical specimens. Furthermore, parallel identiﬁca-
tions of IFV types and subtypes by phylogentic tree analysis were
obtained from MiSeq and Sanger sequencing. No differences in
types of inﬂuenza strains were observed between clinical speci-
mens and viral isolates.
4.3. Nucleotide heterogeneity (variances) and types of mutations
Due to varying concentration (measured as Ct values) of viruses
in the samples, control experiments were conducted and detected
that nucleotide heterogeneity is maintained regardless of the viral
concentration (data not shown).
In general, our data showed that clinical specimens for inﬂuenza
A H3N2 contained less nucleotide heterogeneity than inﬂuenza B
and inﬂuenza A H1N1 (Table 1). Almost all viral isolates, except
VIROAF6, showed a reduction in nucleotide heterogeneity com-
pared to their corresponding clinical specimens. VIROAF3 had
much less nucleotide heterogeneity in the viral isolate as compared
to the clinical specimen. None of the detected variances between
viral isolates and clinical specimens were the same, except two
variances that were observed in both the viral isolate and clinical
specimen of VIROAF1. That we could detect, there were no obvious
inﬂuenza gene that did not undergo some change during cell isola-
tion.Minority of variances leads to nonsynonymousmutations that
are associated with drug resistance or antigenic sites (Table 2).
4.4. Validation of genetics diversity from viral isolate
The majority of viral isolates had lower nucleotide heterogene-
ity or fewer variant sites compared to the corresponding clinical
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specimens. Only few novel variances emerged during culture. The
genetic variance at position 41 of the HA gene viral isolate from
VIROAF2, one of the few variances detected in the isolate but not
in the clinical specimen, was further examined by Sanger sequenc-
ing and pyrosequencing. The mixture of cytosine (C) and thymine
(T) at that position was determined to be 55%:45%, 65%:35% and
73%:27% by Sanger sequencing, deep sequencing and pyrosequenc-
ing, respectively (Fig. 2).All of these threemethodologies conﬁrmed
the presence ofmixed bases in this viral isolatewhile only thymine
was present in the clinical specimen at this position.
5. Conclusions
Six acute IFV-positive clinical specimens and their viral isolates
were sequenced using deep sequencing techniques [13,29–31].
The clinical specimens/isolates were identiﬁed as having three
inﬂuenza A H3N2, one 2009 inﬂuenza A H1N1 and two inﬂuenza
B. Our maximum-likelihood phylogenetic tree analysis calculated
the genetic distance between the consensus sequences of clini-
cal specimens and the corresponding viral isolates as less than 5%,
suggesting only a slight genome divergence caused by MDCK cell
culture ampliﬁcation of the virus. Regardless of DOC, therewas less
nucleotide heterogeneity in viral isolates than in clinical specimens
in 5 of 6 cases.
These results suggest that viral propagation using mammalian
cells reduces the viral population diversity that exists in clinical
specimens, similarly to previous observations (21, 29). In variance
sites in samples with DOC higher than 10, genetic variancesmostly
reﬂected synonymousmutations.Overall,most of thevirus genome
remained unaffected byMDCK cell culture isolation, as seen by the
minimal differences in the consensus sequences between the viral
isolates and clinical specimens (Fig. 1).
Genetic variances in the clinical samples tended to disappear
after cell-based isolation. This may have been caused by the low
recoveryof viral subpopulations afterMDCK isolation, orbyadapta-
tion of viral populations in MDCK cells. However, in rare instances,
new variances appeared in the isolates. Using pyrosequencing and
Sanger sequencing, we conﬁrmed a variance at nucleotide posi-
tion 41 of the HA gene of VIROAF2, which contained a thymine
residue in the clinical specimen but a cytosine/thymine mixture in
the viral isolate. This result demonstrates that Sanger sequencing
and pyrosequencing can be used to validate deep sequencing.
Genetic divergence from clinical specimens to viral isolates
has been documented previously. Several groups observed host-
dependent variations in the HA and NA genes of inﬂuenza A H3N2,
inﬂuenza A H1N1 and inﬂuenza B (18–21). Zhirnov et al., 2009 and
Roedig et al., 2009 reported changes of HA and NA gene especially
in the glycosylation sites of inﬂuenza A by Sanger sequencing [1]
and pyrosequencing [11], respectively. Overall, our results yielded
slightly different ﬁndings compared to these reports. We found far
fewer numbers of nonsynonymousmutations in viral isolates com-
pared to the clinical specimens. The alteration of amino acids in
nonsynonymous mutations in our study do not match any of the
A, B, C, D and E antigenic sites as deﬁned previously by Kobayashi
and Suzuki et al., 2012 and Lee and Chen et al., 2004 [32,33] for
inﬂuenza AH3 and deﬁned by Caton et al., 1982 for inﬂuenza H1N1
[34]. Our observations on the antigenic sites are similar to the pre-
vious report [1]. Almost all variances are not associated to antiviral
drug resistance and any reported antigenic sites as reported by
several studies [25–28]. Only D151N mutation in the NA gene, an
oseltamivir resistant phenotype although other studies may sug-
gest otherwise [35], was detected in viral isolate and not primary
clinical specimen from VIROAF1. Nonetheless, the presence of the
nonsynonymousmutations from one point of culturemight be due
to the PCR or sequencing errors as previous described [36].
In summary, deep sequencing by MiSeq provided sufﬁcient
comprehensive IFV sequence data to compare clinical specimens
and viral isolates. Identiﬁcation of IFV was comparable to tradi-
tional molecular and culture methods with additionally higher
ability todetect variancemutationsdue tohigherdepthof sequence
information. Our results demonstrate that a substantial decrease
in nucleotide heterogeneity occurs from clinical specimens to viral
cultures; and new mutations may develop during the viral isola-
tion process. Our study was limited by the analysis of only 6 pairs
of inﬂuenza clinical specimens and viral isolates. Further reﬁne-
ment with higher numbers of samples with higher viral quantities
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